advertisement
On 11 July 2018, Hari Shankar, project director at Delhi Network of Positive People (DNP Plus), an NGO that functions as a support group for individuals with HIV/AIDS, was fraught with a usual crisis.
Among the eleven government-run ART (Anti-Retroviral Therapy) centres in Delhi, one had run out of HIV drugs.
This was not an unprecedented situation in India’s capital where stock-out or shortage of HIV drugs is quite common.
Hari Shankar bought drugs for HIV patients who had come from the states of Rajasthan, MP and included locals from Delhi as well.
In a series of at least five letters, written since June, that are addressed to the National AIDS Control Organisation (NACO), activists associated with DNP Plus have requested the concerned authorities to ensure that buffer stock of HIV drugs is available at all the ART centres.
In one such letter written on 14 September 2018, which is addressed to the Deputy Director General in Care, Support & Treatment division of NACO, a request was made to ensure that NVP (nevirapine) syrup is available at AIIMS. NVP is administered as part of anti-retroviral therapy to prevent mother-to-child transmission of HIV.
On 29 August 2018, the Lok Nayak Hospital ran out of HIV medicine yet again, reported the Hindustan Times. It was the third line drug combination of Raltegravir, Darunavir and Ritonavir which was not available at the government hospital.
‘The drugs are centrally procured for the entire country by the National AIDS Control Organisation (NACO). However, there were problems in finalizing the tender and hence there is a shortage across Delhi’, an official at Delhi’s health department told the Hindustan Times.
Difference in costs between the first line and third line drug combination explains why HIV patients flock to government-run ART centres to get prescribed medicines.
While the first line HIV drug combination costs somewhere between Rs 1,000-Rs 3,000 for a month, the price for third line drug combination for 30 days is between Rs 20,000-Rs 25,000.
According to Dr Pooja Khosla, Senior Consultant at Sir Ganga Ram Hospital, “HIV virus is very vulnerable to resistance and skipping of drugs may lead to mutation and thus, the first line of drugs will stop working”.
Dr Khosla who is associated with the Department of Medicine with her primary interest being HIV says:
In 2016, an HIV positive woman filed a PIL at Delhi High Court alleging that ‘ART centres did not have sufficient stock of antiretorvirals, as patients were being given medicines for only 15 days at a time.’
Speaking to FIT, the petitioner says, while the residents of Delhi struggle to get HIV drugs, its even worse for those who come here from other states.
Listen in to the petitioner who approached the Delhi HC over shortage of HIV drugs. Voice has been distorted to protect the woman’s identity.
On 18 November 2018, the Delhi High Court sought a response from the Ministry of Health after the woman filed a contempt petition against the Centre, AAP govt and NACO. Next hearing in the case is expected on 12 March 2019.
Loon Gangte, an activist with Delhi Network of Positive People, who is an HIV positive himself, says that situation hasn’t improved since 2004 when they started monitoring stock-out of AIDS drugs.
Gangte now refers to these mails as ‘laugh letters’. There was a big hue and cry after the BJP-led government had slashed NACO’s budget to Rs 1,397 crore, a decrease of 22 percent in 2015-16. However, the budget was increased by 17.65 percent from Rs 1700 crore in 2016-17 to Rs 2,000 crore for the year 2017-18.
Activist Loon Gangte who has been on HIV treatment since 2002 says while there is no shortage of budget, there are structural problems with NACO that explain the problem of stock-out.
On 15 October 2018, in a column titled ‘AIDS Control in India Losing Momentum’, JVR Prasada Rao, former Union Health Secretary who was the Director General of NACO between 1997 and 2002 wrote:
Targeted Interventions (TIs) refers to providing prevention and care facilities to high risk populations.
According to activist Deepak Rana who works with Alliance India, an NGO that works in the area of prevention of HIV/AIDS, convincing those belonging to high risk population for regular check-ups is a challenge. ‘We keep on tracking their progress as the High Risk Group (HRG) comprising sex workers needs to undergo HIV test every six months’, says Deepak.
Alliance India focuses on the High Risk Group (HRG) comprising sex workers and transgenders and lately has started approaching spas and massage parlours in Delhi, in a bid to spread awareness about use of condoms.
An activist who did not want to be named and works with an NGO that helps HIV/AIDS patients said, ‘Initially, it was the duty of State AIDS organisations to procure drugs and condoms directly from NACO. But ever since the NHM (National Health Mission) came into picture since 2013, the problem began.’
Perhaps it’s for this reason that activists like Loon Gangte who have raised concerns about India’s AIDS prevention programme for almost two decades are now demanding that NACO should be given autonomy.
In a country where approximately 21.40 lakh people are living with HIV-AIDS (as per a 2017 report by NACO), perhaps it’s time when skewed policy decisions need a re-look.
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)
Published: 28 Nov 2018,05:39 PM IST